Partners take on cancer and heart disease


Friday, 13 November, 2020


Partners take on cancer and heart disease

Advanced medical imaging provider GE Healthcare and provider of integrated cancer and cardiovascular care GenesisCare have partnered to tackle the globe’s greatest health burdens: cancer and cardiovascular disease. The partnership aims to achieve earlier, faster and more confident cancer diagnosis and more precise intervention and individualised treatment, leading to better patient outcomes.

The multiyear strategic partnership — valued at more than US$130 million — will enable Australian-headquartered GenesisCare to offer patients greater access to leading technology, with a plan to explore further collaborations to improve cancer diagnosis, treatment and cardiovascular care.

GE HealthCare will supply and service the latest CT, MRI, PET/CT, SPECT, digital mammography and ultrasound equipment to 440+ GenesisCare cancer and cardiovascular treatment centres across Australia, the US, the UK and Spain.

The partnership marries GenesisCare’s leadership in the delivery of cancer and cardiac screening, diagnosis and treatments with GE Healthcare’s world-class imaging technologies, digital infrastructure, oncology and cardiology solutions, data analytics, and clinical decision support capabilities.

GenesisCare recently acquired major US integrated cancer care provider 21st Century Oncology, increasing access to cancer care for patients across US communities as well as its global network.

Separately, the companies plan to explore further partnership on research activities, with the aim of improving clinical care and outcomes for millions of patients around the world, through technology, education, care pathway development and theranostics — an innovative and personalised approach that combines molecular imaging and radiotherapy to seek and destroy advanced cancers without damaging healthy tissue.

Cardiovascular disease, followed by cancer, is the leading cause of death globally.1,2 Cases are predicted to increase by more than 60% over the next 20 years.3 GE Healthcare’s diagnostic imaging and monitoring portfolio can be deployed throughout a patient’s cancer or cardiac journey — from initial screening and diagnosis, through to therapy guidance facilitating minimally invasive treatment, and monitoring patient progress.

“Together with GenesisCare, we aim to offer patients greater access to leading medical technologies, more precise intervention and individualised treatment, leading to a new standard of personalised health care,” GE Healthcare President and CEO Kieran Murphy said.

“We hope that combining GenesisCare’s clinical excellence with GE Healthcare’s medical diagnostic innovation and AI capabilities will positively impact millions of cancer and cardiac patients.”

GenesisCare founder and Global CEO Dan Collins said it is important to continue to increase investment and access for doctors and patients during the current COVID-19 pandemic.

“Cancer and heart disease haven’t stopped during this pandemic, and high-quality imaging and diagnosis will be in greater demand than ever as many people begin to feel more comfortable accessing screening services,” he said.

“Our new global partnership with GE Healthcare will allow for better patient access to state-of-the-art technology and exciting research collaborations that will raise the bar in delivering care for patients of the future. We are delighted to partner with US-headquartered GE Healthcare to help ensure that cancer patients, in our more than 290 treatment locations across the US, receive rapid access to the latest advancements in oncology treatments.”

References

  1. https://www.who.int/news-room/fact-sheets/detail/cancer
  2. https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
  3. https://www.who.int/news-room/detail/04-02-2020-who-outlines-steps-to-save-7-million-lives-from-cancer

Image courtesy of GenesisCare

Related News

Research reveals gaps in adult pertussis vaccination

Older Australians may be missing out on protection against pertussis because GPs tend to focus on...

How long until the leading vaccines make it to market?

Pfizer and BioNTech may face major hurdles in getting their vaccine to market, despite recently...

The most common and costly drugs of 2019–2020

Which prescription medicines are most commonly used in Australia? Which have the greatest cost to...


  • All content Copyright © 2020 Westwick-Farrow Pty Ltd